Integra LifeSciences Holdings Corporation (NASDAQ:IART) Stock Rated “Reduce” by Sell-Side Brokerages

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has earned an average recommendation of “Reduce” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $17.29.

IART has been the subject of a number of research analyst reports. Wells Fargo & Company set a $15.00 target price on shares of Integra LifeSciences in a research note on Saturday, October 3rd. Weiss Ratings downgraded shares of Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Citigroup restated a “neutral” rating and set a $15.00 target price (down from $19.00) on shares of Integra LifeSciences in a report on Monday, October 5th. Wall Street Zen lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, UBS Group began coverage on Integra LifeSciences in a research note on Tuesday, July 28th. They set a “neutral” rating and a $19.00 target price for the company.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Paradigm Capital Management Inc. NY increased its position in shares of Integra LifeSciences by 50.6% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after purchasing an additional 1,347,700 shares during the last quarter. Wellington Management Group LLP grew its stake in Integra LifeSciences by 12.4% in the 2nd quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after buying an additional 160,814 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Integra LifeSciences by 71.4% during the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after purchasing an additional 589,408 shares during the period. Invenomic Capital Management LP lifted its holdings in shares of Integra LifeSciences by 78.3% during the fourth quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock worth $13,115,000 after buying an additional 463,729 shares in the last quarter. Finally, Glenmede Trust Co. NA raised its stake in Integra LifeSciences by 27.4% in the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after purchasing an additional 211,774 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Integra LifeSciences stock traded down $0.15 on Tuesday, hitting $13.83. The company’s stock had a trading volume of 76,916 shares, compared to its average volume of 899,314. The firm has a market cap of $1.08 billion, a P/E ratio of -153.17, a price-to-earnings-growth ratio of 0.69 and a beta of 1.21. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a one year low of $8.70 and a one year high of $20.49. The company has a fifty day moving average price of $16.15 and a 200-day moving average price of $15.37.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%. The company had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.